American Bio Medica Receives NASDAQ Delinquency Notice

Company previously reported minimum bid non-compliance in Form 8-K last week

KINDERHOOK, N.Y.--(BUSINESS WIRE)--Nov. 19, 2007--American Bio Medica Corporation (NASDAQ:ABMC) announced today that, as previously reported in its Current Report on Form 8-K filed with the Securities and Exchange Commission on November 13, 2007, the Company received a notice from the Nasdaq Stock Market on November 12, 2007 informing the Company that for the last 30 consecutive business days, the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 4310(c)(4).

The letter stated that under Marketplace Rule 4310(c)(8)(D), the Company will be provided with 180 calendar days, or until May 12, 2008, to regain compliance with Marketplace Rule 4310(c)(4). To regain compliance, anytime before May 12, 2008, the bid price of the Company's common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days.

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid TEC(R), RDS(R) InCup(R), Rapid TOX(R) and Rapid TOX Cup(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat(R) and Rapid STAT(TM) tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(R) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2006, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

    CONTACT: American Bio Medica Corporation
             Stan Cipkowski, Chief Executive Officer,
             800/227-1243, Ext 106
             or
             BPC Financial Marketing
             John Baldissera, 800/368-1217

    SOURCE: American Bio Medica Corporation